Patent: 9,862,767
✉ Email this page to a colleague
Summary for Patent: 9,862,767
Title: | Therapeutic methods using anti-CD200 antibodies |
Abstract: | The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent. |
Inventor(s): | Rother; Russell P. (Oklahoma City, OK), Yan; Yan (Cheshire, CT) |
Assignee: | Alexion Pharmaceuticals, Inc. (New Haven, CT) |
Application Number: | 14/739,862 |
Patent Claims: | see list of patent claims |
Details for Patent 9,862,767
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-02-11 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2030-02-11 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2030-02-11 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2030-02-11 |
Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 03/28/2017 | ⤷ Try a Trial | 2030-02-11 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2030-02-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |